Abstract
Leishmaniasis and Chagas disease are endemic in many countries, and re-emerging in the developed countries. A rapid and accurate diagnosis is important for early treatment for reducing the duration of infection as well as for preventing further potential health complications. In this work, we have developed a novel colorimetric molecular assay that integrates nucleic acid analysis by dynamic chemistry (ChemNAT) with reverse dot-blot hybridization in an array format for a rapid and easy discrimination of Leishmania major and Trypanosoma cruzi. The assay consists of a singleplex PCR step that amplifies a highly homologous DNA sequence which encodes for the RNA component of the large ribosome subunit. The amplicons of the two different parasites differ between them by single nucleotide variations, known as “Single Nucleotide Fingerprint” (SNF) markers. The SNF markers can be easily identified by naked eye using a novel micro Spin-Tube device "Spin-Tube", as each of them creates a specific spot pattern. Moreover, the direct use of ribosomal RNA without requiring the PCR pre-amplification step is also feasible, further increasing the simplicity of the assay. The molecular assay delivers sensitivity capable of identifying up to 8.7 copies per µL with single mismatch specificity. The Spin-Tube thus represents an innovative solution providing benefits in terms of time, cost, and simplicity, all of which are crucial for the diagnosis of infectious disease in developing countries.
Introduction
Parasitic diseases not only cause millions of deaths per year, but also have serious health and economic consequences1. Among all the parasitic diseases, protozoan parasites of the family Trypanosomatidae are responsible for devastating diseases in humans, dogs as well as livestock, resulting in severe illness or even death if left untreated1,2. The protozoa Trypanosoma cruzi (T. cruzi) and Leishmania spp. are the causative agents of Chagas disease and Leishmaniasis respectively3. Even though these diseases are endemic in tropical and sub-tropical regions of the world, in the last decades there has been a re-emergence also in developed countries, with international travel being responsible for increases in reported cases of Trypanosomatidae infections in non-endemic countries1,4. Consequently, these parasitic infections have become a more important public health issue of global relevance. Even though there are several methods available for the screening of parasitic infections, however, they have not yet changed dramatically the diagnosis in developing countries. Microscopic identification and parasite cultivation are still the primary diagnostic tools employed in many regions where Leishmaniasis is endemic5. These methods, unfortunately, require extended incubation times and are expensive, requiring specialized equipment and highly trained personnel6. On the other hand, standard serological approaches that could potentially prove to be timely and cost effective for diagnosing parasitic infections are of limited value, as most patients do not develop a significant antibody response7. In addition, and problematically for clinicians attempting to make an accurate diagnosis, T. cruzi and Leishmania spp. share various antigens that cause cross-reactivity in serological diagnosis when complex antigenic mixtures are used8. As a result, Nucleic Acid Testing (NAT) methodologies have become valuable methods for the routine and accurate assessment of parasitic infectious diseases. NAT benefits from the presence of specific nucleic acid fragments for determining the presence/absence of pathogens3,9–13. There are different methods ranging from probe hybridization, amplification of genomic targets and sequencing of nucleic acid fragments. The use of Nucleic Acid Amplification Techniques (NAATs) such as Polymerase Chain Reaction (PCR), real-time PCR or Nucleic Acid Sequence Based Amplification (NASBA) can be very useful in detecting infections and post-treatment monitoring9,13,14, including detection and distinguishing of parasites using single base resolution methods such as Single Base Extension (SBE). Primers are designed to hybridize to a complementary nucleic acid region such that the 3′ end of the primer finishes immediately before the nucleotide under interrogation15. However, while NAT has the advantage of being sensitive, there are some limitations, as the NAT methodologies have complex protocols, require technical expertise to run and interpret data (not cost-effective), and utilize equipment that is incompatible with use in remote and low-resource locations, such as developing countries where diagnostic laboratories are often poorly resourced and sparsely distributed16. Thus, there is an urgent need for early detection of infectious disease with improved, simple and low-cost alternative tests not requiring expensive laboratory equipment to be performed. To sum up, while laboratory-based models require benchtop laboratory facilities and complex procedures, Point-of-Care testing allows a more decentralized diagnostic analysis with additional advantages such as portability, automation, shorter time-to-results and lower cost17–19. The World Health Organization (WHO) is consistently encouraging developers to implement these new diagnostic technologies for improved effective clinical management and treatment of the major infections suitable in developing countries context20,21. These diagnostic devices should follow WHO criteria, the ASSURED acronym (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable)22,23. Following this encouragement, Zhang et al. recently developed a low-cost CRISPR-based diagnostic (CRISPR-Dx) for detecting DNA or RNA molecules of pathogenic species with single mismatch specificity24,25.
Besides the tests available today19,26, our group has recently reported the successful detection and differentiation of three Trypanosomatids species, by detecting Single Nucleotide Fingerprint (SNF) markers using a dynamic chemical approach for nucleic acid reading (ChemNAT technology)27,28 in combination with MALDI-ToF29. SNF markers are single nucleotide variations that occur at specific positions in conserved target nucleic acid sequences, allowing the differentiation of pathogenic species. As a result, these SNF represents the perfect target to be interrogated by the ChemNAT technology through the specific dynamic incorporation of aldehyde-modified SMART-Nucleobases into the abasic position of abasic PNA probes. Despite its high specificity, the use of this method has limitations, with higher cost and complex instrumentation (MALDI-ToF) required, making this approach unsuitable for diagnosis of parasitic infections in developing countries.
Here, we report the adaptation of our previous method onto a colorimetric reverse dot-blot30–35 assay that has the potential to fulfil the WHO ASSURED criteria, for the diagnosis of Leishmaniasis and Chagas disease. This novel method combines ChemNAT technology with a simple colorimetric end-point assay on a porous nylon membrane contained within a micro Spin-Tube device (Spin-Tube). The assay uses a singleplex PCR to amplify a highly conserved sequence of DNA, which encodes the RNA component of the large ribosome subunit with SNF markers for the two different parasite species under interrogation. This amplicon is later interrogated by the ChemNAT technology that relies on a dynamic chemical approach for nucleic acid testing. As shown in Fig. 1, the SNF sequence analysis is based on combining biotinylated aldehyde-modified cytosine (SMART-C-Biotin) with unique abasic PNA probes to target PCR amplicon strands, such that a nucleobase-free position on the PNA strand (known as ‘abasic’ position) lies opposite to two different nucleotides under interrogation on the DNA amplicons. A reversible reaction between the SMART-C-Biotin and a free secondary amine on the abasic PNA probes generates an iminium intermediate, which can be chemically reduced to a stable tertiary amine. Within the novel Spin-Tube, the dynamic chemistry reaction mixture is added to the nylon membranes on which the abasic PNA probes have been immobilized following a specific spot pattern (Fig. 1, Step 1). The PCR amplicons act as template molecules and drive the specific incorporation of SMART-C-Biotin molecules into a specific abasic PNA according to Watson-Crick DNA base pairing model in which the SMART-Cytosine, in this case carrying a biotin tag, is ONLY recognized by a guanidine nucleotide (Fig. 1, Step 2). The labelling is then achieved by streptavidin alkaline phosphatase (Streptavidin-ALP) to produce colorimetric signal (blue precipitate) patterns when the chromogenic substrate (NBT/BCIP, nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-indolyl phosphate) is added. Each parasite gives a unique colored spot pattern that can be read by naked-eye (Fig. 1, step 3).
Results and Discussion
Conserved region amplification and abasic probes design
PCR amplification was carried out to amplify the conserved region encoding for the 28S ribosomal RNA delta genes. As shown from the multiple sequence alignment in Fig. 2A, the PCR amplification of the target sequence was performed using a single pair of primers (singleplex PCR) which amplifies any of the parasite species present in the sample. The target region is highly conserved among the Trypanosomatids T. cruzi and L. major, except for five SNFs. Amplified fragment analysis was performed using the previously described Spin-Tube. Briefly, abasic PNA probes, PNA1 and PNA2 were designed in order to hybridize efficiently with the amplified single strand sense DNA, with the important particularity that the abasic positions in the PNA probes are opposing the nucleobases under interrogation. Once the abasic PNA probes hybridize with target sequences, the SMART-C-Biotin dynamic incorporation takes place, enabling the unequivocal identification of the parasite present in the amplicon sample, because of the unique colorimetric pattern that each Trypanosomatid amplicon generates. As shown in Fig. 2B, the abasic PNA1 probe was designed so that its abasic site lies opposite a guanidine nucleotide (at position + 32 of the amplicon), irrespective of the species, so as to give a positive result for both parasites, thus confirming the presence of one or both Trypanosomatids in the sample (see red arrow in Fig. 2A). At the same time, the abasic PNA2 is the probe that enables discrimination of the Trypanosomatid species. As the target parasite T. cruzi has a guanidine at the position that lines up with the “abasic” position in the abasic PNA2 probe (SNF1 in Fig. 2B), the SMART-C-Biotin incorporation is templated, thereby covalently incorporating the biotin tag into the probe attached to the membrane, resulting in a blue spot after applying the labelling and color development protocol. DNA coming from L. major has the same sequence but with an adenosine at the SNF1 position (instead of a guanine, see Fig. 2B). This DNA hybridizes with PNA2 but SMART-C-Biotin is not incorporated and so no signal is detected on abasic PNA2. In summary, this approach requires two specific molecular events to create a signal: (i) perfect hybridization between nucleic acid strands and complementary abasic PNA probes; and, (ii) specific molecular recognition, through guanidine-cytosine base-pairing to allow SMART-C-Biotin incorporation onto the abasic site of the PNA probes (Fig. 2C).
Spin-Tube fabrication
The ChemNAT technology with its colorimetric reverse dot blot assay (colorimetric ChemNAT assay) was integrated into a novel micro device, known as “Spin-Tube” (Fig. 3A). As shown in Fig. 3B, the Spin-Tube consists of: (i) a centrifuge collection tube; (ii) an internal column for the assay; (iii) a nylon membrane (pre-spotted with abasic PNA probes) immobilized onto the bottom of the column via a plastic pressure ring (iv). The abasic probes were amino-PEGylated at their N-terminal end and printed onto nylon membranes containing pre-activated carboxyl groups (Fig. 3C). An important stage in the construction of the Spin-Tube, apart from the immobilization of abasic PNAs, was the definition of the array probe layout (Fig. 3D). Probes with fixed concentrations were printed with an automatic nano-plotter onto the nylon membrane, and optimization of signal strength and best signal to background ratios was undertaken. Taking into account the 8 mm membrane diameter, it was decided to create a 2 × 3 array. Abasic PNA1 and PNA2 were printed onto two parallel rows of three spots each (6 features in total, in red and blue in Fig. 3D respectively). Two control biotin-labelled DNA oligomers were printed on the top row of the array, to identify array orientation and provide a labelling internal control (in yellow in Fig. 3D). Following printing, performance of probes was initially checked by using synthetic mimic DNA oligomers and SMART-C-Biotin incorporation (data not shown).
Abasic PNA probes design and synthesis
Abasic PNA1 and PNA2 were synthesized with amino-PEGylated groups in order to be covalently bonded and immobilized onto the solid substrate (nylon membranes). As previously described by our group, abasic neutral PNA probes immobilized onto solid surfaces have been found to lack stability and can exhibit a degree of undesirable deformation, flexing and/or bending36. This affects the performance (e.g., specificity and/or sensitivity) of the abasic PNA probes in this assay – preventing maximum target binding and assay performance. Abasic PNA1 and PNA2 were designed and synthesized with these solid surface challenges in mind, adding PNA monomers containing propanoic acid residues at their gamma positions across the probe backbone, improving the probe performance and reducing self-aggregation (Fig. 2B and Fig. S2 in SI). Moreover, these gamma modifications give rise to a sterocenter, hence creating chiral PNAs molecules, being just the L-PNA monomers the ones producing PNA oligomers capable of hybridizing complementary natural nucleic acids37–40. The result was that the L-propanoic abasic PNA probes bound to nylon membrane were more readily available to hybridize to complementary nucleic acid strands. Still unknown was if such abasic PNA probes would prove to be less prone to flexing, bending or otherwise deforming from their “normal” linear configuration36. The modifications introduced led to the two probes demonstrating improved specificity and improved sensitivity towards a base complementary to the nucleobase of the DNA amplicon to be characterized. The abasic position monomer was also modified with this propanoic acid chain at gamma position and with the same stereochemistry allowing a better dynamic incorporation of the SMART-C-Biotin because of the spatial orientation of the free secondary amine of the “blank” position (Fig. S2 in SI).
Labelled SMART Nucleobase for the colorimetric detection
While our previous mass spectrometry method29 allowed parasite species detection and characterization by measurement of molecular weight differences between abasic PNA probes and aldehyde-modified nucleobases (SMART-Bases), in this Spin-Tube platform it was required that the SMART-Base were biotin-labelled (Figs S3–S5 in SI)41,42. Here the color development reaction depends on the biotin recognition by a streptavidin-alkaline phosphatase complex, that transforms a colorless chromogenic substrate (NBT/BCIP, nitro blue tetrazolium chloride/5-Bromo-4-chloro-3-indolyl phosphate) into a blue precipitate each time there is a biotin tag attached to the membrane. The blue spots emerging correspond to those abasic PNA probes which have successfully hybridized with the complementary PCR products and in whose abasic positions SMART-C-Biotin has been incorporated through a guanosine template (Fig. 2). The SMART-C-Biotin bears a PEG spacer to increase water solubility while at the same time distancing the nitrogenous base involved in the hydrogen bonding recognition from the biotin tag responsible for the color development43.
Sequence analysis of genomic DNA
The Spin-Tube platform was validated using PCR products from genomic DNA (gDNA) of both parasites. Singleplex PCR was carried out to amplify the highly conserved segment of DNA containing the two single nucleotides under interrogation (Fig. 2). DNA amplicon products were denatured and then together with the dynamic chemistry reaction reagents added directly into the internal column of the Spin-Tube that supports the nylon membrane for the color-development assay (Fig. 4). Subsequently, the reaction was carried out at a constant temperature of 45 °C avoiding the need to make use of sophisticated apparatus. Single stranded DNA hybridizes with the abasic PNAs acting as template molecules, driving the error free incorporation of SMART-C-Biotin into the specific chemical pocket. Finally, the incorporated SMART-C-Biotin is labelled with a streptavidin-ALP, so that a colorimetric signal pattern was generated when the chromogenic substrate is added. The signal pattern generated by the protocol allows the visual or photographic imaging of which species cause the patient infection. L. major gDNA generated a signal ONLY at the abasic PNA1 probe, as its abasic site lies opposite a guanidine at +32 position from the 5′-terminus of amplicon (see red arrow in Fig. 2). While, T. cruzi gDNA generated signals for both abasic PNA probes. The abasic sites of both PNA probes lie opposite a guanidine, allowing the incorporation of SMART-C-Biotin with its biotin tag, thus resulting in a blue spot after its incorporation. Results in Fig. 4 show a successful identification of parasites present in samples, and in line with the expected results, showing (a) L. major positive for abasic PNA1 ONLY and (b) T. cruzi positive for both abasic PNA probes.
Assay specificity
Bioinformatic along with experimental analysis were carried out to discard the possibility that the presence of human gDNA on the samples could affect the singleplex PCR. Initially, a primer BLAST study was carried out using the NCBI primer BLAST tool and no human hits came out. Primers specificity against human gDNA was experimentally checked. 20 ng of human gDNA were used as PCR template for its amplification with the set of primers described in our study and neither colorimetric signals nor bands were detected using the Spin-Tube and capillary electrophoresis analysis respectively (Fig. 5, column 2: 2A and 2B), hence probing the specificity when human gDNA is present. We also mixed 20 ng of human gDNA with 20 ng of DNA from both Trypanosomatid species in order to perform PCR and amplicon analysis by capillary electrophoresis and Spin-Tube approaches (Fig. 5, column 3: 3A and 3B and column 4: 4A and 4B). It was confirmed that amplicon formation of the Trypanosomatid species and their detection were not affected by the presence of the human gDNA.
In order to clarify the specificity of the PCR towards other microorganisms, an in silico study was carried out (data not shown). 28S ribosomal RNA delta gene sequences from Leishamania spp., Trypanosoma brucei and Trypanosoma cruzi were aligned using EMBL-EMI tool for multiple sequence alignment Clustal Omega to check that not only the primers but also the designed abasic PNA probes were suitable for the Spin-Tube and MALDI-ToF approaches. This tool was also used to study which other Leishmania species were suitable to be submitted to this singleplex PCR. Forward and reverse primers were blasted towards other organisms using NCBI primer BLAST tool. It was found that mainly genome from Trypanosomatids species matched the designed primers. Although, a few other genome sequences could also be amplified by our designed primers (Schistosoma mansoni, Leptomonas pyrrhocoris, Aspergillus sclerotioniger and Aspergillus eucalypticola), all these infectious agents cause diseases with clinical manifestations very different from those manifested in Leishmaniasis and Chagas disease and therefore other diagnostic paths would be proposed. Another key factor of the assay Spin-Tube is the signal emerges after the dynamic incorporation of SMART-C-Biotin into the abasic site of the abasic PNA probes. Even if off-target sequences are amplified, no colored spots will be observed. So, DNA strands coming from any off-target species will not create a signal, as that DNA strends will not have precise homology with both forward and reverse primers, as well as the region complementary to the abasic PNA within a narrow area of its genome.
Assay sensitivity
Clinically relevant sensitivity was achieved using the amplification and detection platform. The assay was challenged by interrogating different PCR amplification reactions, using decreasing amounts of T. cruzi gDNA as starting material. Important to note in this study, 3 biotin markers were printed on the top row of the array, rather than 2 (Fig. 6A). Instead of simple circular plastic-ring (see red arrow in Fig. S1-D in SI), here for the construction of Spin-Tube, pressure plastic-ring with three plastic teeth (see white arrow in Fig. S1-D in SI) were used. Six different amounts of gDNA (50 ng, 5 ng, 0.5 ng, 0.05 ng, 0.005 ng, 0.0005 ng) were studied (Table S1 in SI). PCR amplifications were validated and quantified by capillary electrophoresis. All but the two lowest amounts of gDNA (0.005 ng and 0.0005 ng) produced amplicons which were able to be detected and quantified by capillary electrophoresis (Fig. 6B). The amplification products were then used as template for the dynamic incorporation of SMART-C-Biotin within the Spin-Tube. Positive signals were obtained for both abasic PNAs as anticipated, confirming the presence of T. cruzi (Fig. 6C).
A relative quantification of the signal intensity was carried out using ImageJ software. Average background signal intensity was taken and subtracted from all the measurements. Biotin signal intensity (marker) was used as reference representing 100% intensity. The signal intensity for each abasic PNA probe was extracted and expressed as a percentage of the biotin signal. Almost no difference was observed by eye for the membranes in which 50 and 5 ng of T. cruzi gDNA was used as template for the PCR, whereas the relative signal intensity quantification by ImageJ software showed a slight lowering of signal as the genomic amounts decreased (Fig. 6C). The lowest point which could be detected was 0.05 ng or 8.7 copies/µL of template (see SI, Table S1 for the correlation of ng of gDNA and copy number). No results were observed for the two lowest genomic quantities, respectively 0.05 and 0.005 ng. These results confirm what had been already observed using capillary electrophoresis, further confirming that the limit of detection of the dynamic incorporation assay depends on the PCR yield to provide sufficient template. Reactions in which not enough copies of amplicons were created were mis-called as parasite free, being false negatives. Negative control (made with H2O as template for the PCR) was also called as parasite free, being a true negative result.
Analysis of spiked parasite gDNA in blood
Verma et al. in their previous study44 reported a mean Leishmania parasite load of 8,372 parasites/mL in a group of 29 visceral leishmaniasis patients. In order to determine if the sensitivity of the Spin-Tube is able to detect the levels of infections reported by Verma et al., a spike-in experiment was performed. Two human blood samples were spiked-in with 10 and 0.1 ng of L. major gDNA and total DNA was extracted. Those extracted DNAs were used as template for PCR amplifications and the generated amplicons were analyzed by capillary electrophoresis (Fig. 7A) and by the Spin-Tube (Fig. 7B). The results confirmed that the Spin-Tube is able to detect a minimum of 0.1 ng of L. major gDNA spiked-in 200 μL of whole blood that equals to 5,000 parasite per mL of blood according the previous publication44.
Direct sequence analysis of ribosomal RNA
Since the target nucleic acid of the assay was the sense strand DNA of the gene coding for the 28S rRNA delta unit, RNA could also be used as a target nucleic acid using the dynamic chemistry approach (Fig. 8A). Recently, the dynamic chemistry approach was used to quantify circulating miRNAs41, demonstrating its feasibility to detect both DNA and RNA molecules. Direct detection of ribosomal RNA would avoid performing DNA pre-amplification steps by PCR and denaturation and could significantly simplify and shorten the protocol. This would allow its implementation in developing and resources-limited countries.
A proof-of-concept study was carried out using RNA as the templating nucleic acid. Total RNA from both parasites L. major and T. cruzi was used. RNA quality and quantitation were determined using an Agilent 2100 Bioanalyzer and RNA 6000 Nano kit (Fig. S7 in SI). Total RNA was fragmented enzymatically, breaking down RNA strands into small segments to facilitate the subsequent hybridization with complementary abasic PNA probes. RNA fragmentation was checked using RNA Pico kit on an Agilent 2100 Bioanalyzer as shown in SI, Fig. S8. Dynamic incorporation of SMART-C-Biotin was performed using 10 µM of SMART-C-Biotin and 1 mM of sodium cyanoborohydride for 1 hour. The results obtained coincided with those obtained when using PCR products. L. major gave positive results for PNA1 and T. cruzi provided a positive signal for both PNA probes (Fig. 8B). This was a breakthrough achievement, demonstrating for the first time that direct, PCR free parasite identification from RNA samples was achieved. In addition, a much shorter protocol was developed while at the same time reducing the possibility of cross-contamination. This demostrated that RNA can also be considered as a biomarker source for the ChemNAT approach and a future application of the Spin-Tube.
Material and Methods
General
All chemicals were obtained from Sigma Aldrich and used as received. SCD buffer was prepared from 2x saline sodium citrate (SSC) and 0.1% sodium dodecyl sulphate (SDS) with the pH adjusted to 6.0 using HCl. All synthetic DNA oligomers (desalted) were purchased from Microsynth AG (Balgach, Switzerland). The two abasic PNA probes (Abasic PNA1 and PNA2) were synthesized by DestiNA Genomica SL (Spain) using standard solid-phase synthesis techniques on an Intavis Bioanalytical Instruments MultiPrep CF Synthesizer (Intavis AG GmH, Germany). Aqueous solutions of abasic PNA probes were prepared and concentrations were determined using a NanoDrop ND-1000 spectrophotometer version 3.3.1. (Thermo Fisher Scientific) using as extinction coefficient values (Ɛ260) either 6.6, 8.8, 13.7 and 11.7 (mM−1 cm−1) for C, T, A, G, respectively. SMART-C-Biotin was prepared by DestiNA Genomica SL (Spain) as reported elsewhere28. Buffers and dilution reagents were provided by Master Diagnostica SL (Spain). The composition of reagents I to VI is property of Vitro SA (Spain).
Genomic DNA samples
Parasitic protozoa genomic DNAs (gDNAs) were purchased from the American Type Culture Collection (ATCC). Respectively, gDNA from T. cruzi strain Tulahuen with ATCC ID 30266D and gDNA from L. major with ATCC ID 30012D. Human gDNA was extracted from MUM-2B cell line provided by J.C. Rodríguez-Manzaneque’s laboratory.
Target nucleic acid selection
Multiple sequence alignment of the 28S rRNA delta genes of L. major vs. T. cruzi was carried out using the Clustal Omega, a free on-line available multiple sequence alignment tool offered by EMBL-EBI.
BLAST studies were carried out with the NCBI primer BLAST tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/primertool.cgi?ctg_time=1534265329&job_key=NT_qawTpCUEufxN6Hho3SGQBJnpJEj1nSA).
PCR Amplification
Alignment results were used to design a single pair of primers able to amplify the target region of both parasites. Primers (5'-3') sequences were: Forward: GATTGTGAAGGGATCTCGCAG and Reverse: TCTGGCTTAGAGGCGTTCA. PCR amplification was performed on a Veriti 96-well Thermal cycler (Thermo Fisher Scientific). Cycling conditions for PCR were as follows: (1) initial denaturation at 96 °C for 3 min; (2) 40 cycles of (a) denaturation 96 °C for 30 sec, (b) annealing at 61 °C for 30 sec, and (c) extension at 72 °C for 30 sec; (3) final extension at 72 °C for 10 sec; (4) final hold at 4 °C. 5 µL of gDNA solutions containing different amounts of gDNA solution for L. major or T. cruzi were amplified using 1X PCR master mix (Thermo Fisher Scientific), 0.15 µM forward and reverse primers per reaction with a final volume of 50 µL. DNA templates were replaced with water for negative controls. PCR reactions were confirmed by capillary electrophoresis using the Agilent 2100 Bioanalyzer and DNA 1000 Kit.
RNA fragmentation
RNA was extracted from parasites as described elsewhere45. RNA quality assessment and quantitation were determined using the Agilent 2100 Bioanalyzer and RNA 6000 Pico Kit (Fig. S7 in SI). NEBNext Magnesium RNA Fragmentation Module Protocol was used to fragment RNA. The following reagents were mixed in a sterile PCR tube: 1–18 µL of purified RNA containing 2–50 µg of total RNA, 2 µL of RNA fragmentation buffer and complete with nuclease-free water up to 20 µL. The mixture was incubated at 94 °C for 5 minutes (to get fragments of around 200-mer length). Then the tube was transferred to ice and 2 µL of RNA Fragmentation stop solution were added. The fragmented RNA was cleaned up using ethanol precipitation: 22 µL of fragmented RNA, 2 µL of 3 M sodium acetate pH 5.2 and 60 µL of 100% ethanol. The mixture was incubated at -80 °C for 30 minutes and then centrifuged at 14,000 r.p.m. for 25 minutes at 4 °C and ethanol was removed carefully. The pellet was washed with 300 µL of 70% ethanol, centrifuged and removed the ethanol. Finally, the pellet was air-dry for up to 10 minutes at room temperature and re-suspended in 13.5 µL of nuclease-free water. To assess the yield and size distribution of the fragmented RNA, 1 µL of a 10-fold dilution was analyzed using the Agilent 2100 Bioanalyzer and RNA 6000 Pico Kit analysis (Fig. S8 in SI).
Abasic PNA probes spotting
An automatic immobilization of the probes on the membranes was done using Personal Arrayer 16 (CapitalBio Corporation, China). Immunodyne ABC Membrane was purchased from Pall Corporation (US). Abasic PNA probe spotting solutions were prepared to have the following final reagents concentrations 0.2025 mg/mL amaranth dye, 0.125 M sodium bicarbonate, 30% of DMSO and 15 µM abasic PNA probe.
Spin-Tube: SMART-C-Biotin dynamic incorporation reaction on membranes and colorimetric readout
Reaction mixtures with a final volume of 300 µL were prepared by mixing: 45 µL of PCR products, 15 µL of SMART-C-Biotin (200 µM), 20 µL of sodium cyanoborohydride (NaBH3CN) - 15 mM in water, and 220 µL of SCD buffer. Protocol: All steps were performed using 300 µL and Spin-Tube devices were centrifuged to discard the solutions between each step. Membranes were incubated for 2 minutes at 45 °C with 300 µL of SCD buffer. The reaction mixture was added and incubated at 45 °C for 60 minutes. Upon completion of the incubation, three post-reaction washing steps were carried out using reagent I (pre-heated at 45 °C). This was followed by a blocking step in which membranes were incubated with reagent II for 5 minutes at RT. The enzymatic reaction was carried out by incubating the membranes with reagent III at RT for 5 minutes. Four post-enzymatic reaction washing steps with reagent IV were carried out. The chromogen solution (reagent V) was added to the membranes and left at 41 °C for 5 minutes. Finally, three post-chromogen washing steps with reagent VI were carried out. Membranes were able to be analyzed.
Sensitivity and specificity of the assay
To assess the specificity of the assay, four tests were carried out: (1) one in which the PCR contained water instead of gDNAs and (2) another one in which 20 ng of human gDNA was used as template; and two more tests in which 20 ng of human gDNA were mixed with other 20 ng of each parasite (Fig. 5). On the other hand, for the sensitivity study, a range of PCR amplification reactions were performed using decreasing amounts of starting T. cruzi gDNA. Six different concentration points (10-fold dilutions) plus a negative control (water) were used in triplicate. All PCR amplification products were analyzed by capillary electrophoresis to determine the amount, if any, of amplicon had been generated (Fig. 5 for specificity and Fig. 6 and Table S1 for sensitivity). Expected size of amplicons were detected when the PCR was performed using the four highest amount of parasitic gDNAs while no bands were detected neither when using just human gDNA nor when using 0.1 and 0.01 pg/µL (Fig. 6B). Negative control (water) has not shown any signal, being truly a negative and so being effectively called as parasite free.
L. major gDNA spike-in experiments on blood
DNA was extracted from 200 µL of human whole blood samples using QIAamp DNA Blood mini kit (Qiagen, Germany) following manufacturer’s guidelines. After proteinase K treatment, two samples were spiked with 10 and 0.1 ng of L. major gDNA. Then, the next steps of the DNA extraction protocol were followed as recommended. Samples were eluted in 30 µL of elution buffer AE. DNA was quantified with NanoDrop ND-1000 spectrophotometer version 3.3.1. (Thermo Fisher Scientific). PCR reactions were performed with a fix amount of DNA, 450 ng. After that, PCR were analyzed by capillary electrophoresis (using the Agilent 2100 Bioanalyzer and DNA 1000 Kit) and by the Spin-Tube.
Conclusions
Our previous SNF sequence analysis by mass-based assay (MALDI-ToF) for trypanosomiasis identification has been further developed onto a new ultra-low-cost, easy and fast to use (~3 hours/test) Spin-Tube device. This novel device was designed to combine the dynamic chemical approach for nucleic acid reading (ChemNAT technology) with a colorimetric method in a plastic column and nylon membrane device (Spin-Tube). The Spin-Tube accurately distinguish and identify Chagas disease vs. Leishmaniasis. The test consists of a singleplex PCR to amplify a highly conserved sequence of DNA, that encodes the RNA component of the large ribosome subunit containing SNFs from the two different parasite species under interrogation. Amplicon identification to single base resolution was achieved. Dynamic chemistry enables preformans in a simple Spin-Tube. The assay allows for a naked-eye read-out of the unique colorimetric patterns coming for sample analysis. Clinical treatment decisions can be made without any ancillary equipment. The proposed Spin-Tube assay not only allows the detection of the presence of Trypanosomatid pathogens, but also differential diagnosis of Leishmaniasis vs. Chagas disease. Multiplexing is achieved by coupling various target-specific abasic probes onto nylon membranes using different array layouts and patterns. Incorporation of SMART-Biotin only into target sequences ensure high specificity. Clinically relevant sensitivity was obtained using our amplification and detection platform, down to a level of detection of 0.001 ng/µL (8.7 copies per µL) of gDNA from pathogen. Moreover, 0.1 ng of L. major gDNA was successfully detected when spiked-in with human blood samples. The assay has demonstrated a clinically relevant sensitivity and specificity44. A remarkable achievement was for the first time to succeed in the direct detection of ribosomal RNA. It opens up the possibility for direct detection of Trypanosomatids from biological fluids without any pre-amplification or pre-labelling of target nucleic acids. This breakthrough provides a prototype assay for an innovative PCR free product with many inherent benefits such as lower cross-contamination risk, simplification of protocol, reduction of time-to-results, significantly lower cost, to insure far lower risk of assay result errors. Concluding, we believe that the Spin-Tube developed by our group provides an accurate tool conbianing high sensitivity and specificity, permitting rapid identification and differential diagnosis of Chagas disease and Leishmaniasis. Its clinical value will be an improved patient monitoring and therapeutic decision making. The Spin-Tube opens-up the promise of repertoire of assays for other infectious diseases, such as malaria and tuberculosis.
Supplementary information
Acknowledgements
This research work has received funding from Junta de Andalucía, Consejería de Economía e Innovación (project number 2012-BIO1778), the Spanish Ministerio de Economía y Competitividad (Grants CTQ2012-34778, BIO2016-80519-R, FPI Grant BES-2013- 063020). This research was partially supported by the 7th European Community Framework Program (FP7-PEOPLE-2012-CIG-Project Number 322276). The Unidad de Excelencia de Química aplicada a biomedicina y medioambiente of the University of Granada. The authors thank DestiNA Genomica SL for the support throughout the entire period work. We also thank you Mr. Hugh Ilyine for proof-reading and J.C. Rodríguez-Manzaneque’s laboratory for providing human gDNA samples.
Author Contributions
Study design: R.M.S.M., S.P. and J.J.D.M. Spin-Tube development: M.T.C., P.E.A., S.P. and J.J.D.M. Spin-Tube development and validation: M.A.L.G., M.T.C., S.P. and A.M.R. Manuscript writing: M.A.L.G., S.P. and J.J.D.M.
Data Availability
All data and information are available upon request.
Competing Interests
J.J.D.M. is shareholder and Director of DestiNA Genomics Ltd. S.P. is shareholder of DestiNA Genomics Ltd.
Footnotes
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mavys Tabraue-Chávez and María Angélica Luque-González contributed equally.
Contributor Information
Salvatore Pernagallo, Email: salvatore@destinagenomics.com.
Juan José Díaz-Mochón, Email: juanjose.diaz@genyo.es.
Supplementary information
Supplementary information accompanies this paper at 10.1038/s41598-019-39946-0.
References
- 1.Ricciardi A, Ndao M. Diagnosis of Parasitic Infections: What's Going On? J Biomol Screen. 2015;20:6–21. doi: 10.1177/1087057114548065. [DOI] [PubMed] [Google Scholar]
- 2.Duncan R. Advancing Molecular Diagnostics for Trypanosomatid Parasites COMMENT. J Mol Diagn. 2014;16:379–381. doi: 10.1016/j.jmoldx.2014.04.001. [DOI] [PubMed] [Google Scholar]
- 3.Lopes AH, et al. Trypanosomatids Odd Organisms Devastating Diseases. The Open Parasitology Journal. 2010;4:30–59. doi: 10.2174/1874421401004010030. [DOI] [Google Scholar]
- 4.Sanchez-Ovejero C, et al. Sensing parasites: Proteomic and advanced bio-detection alternatives. J Proteomics. 2016;136:145–156. doi: 10.1016/j.jprot.2015.12.030. [DOI] [PubMed] [Google Scholar]
- 5.Rosenblatt JE. Laboratory diagnosis of infections due to blood and tissue parasites. Clin Infect Dis. 2009;49:1103–1108. doi: 10.1086/605574. [DOI] [PubMed] [Google Scholar]
- 6.Saeed, M. A. & Jabbar, A. “Smart Diagnosis” of Parasitic Diseases by Use of Smartphones. J Clin Microbiol56 (2018). [DOI] [PMC free article] [PubMed]
- 7.Geiger A, et al. Escaping Deleterious Immune Response in Their Hosts: Lessons from Trypanosomatids. Frontiers in immunology. 2016;7:212. doi: 10.3389/fimmu.2016.00212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Troncarelli MZ, Camargo JB, Machado JG, Lucheis SB, Langoni H. Leishmania spp. and/or Trypanosoma cruzi diagnosis in dogs from endemic and nonendemic areas for canine visceral leishmaniasis. Vet Parasitol. 2009;164:118–123. doi: 10.1016/j.vetpar.2009.06.027. [DOI] [PubMed] [Google Scholar]
- 9.Hernández, C. & Ramírez, J. D. Molecular Diagnosis of Vector-Borne Parasitic Diseases.pdf. Air and Water Borne Diseases2, 10.4172/21677719.1000110 (2013).
- 10.O'Connor L, Glynn B. Recent advances in the development of nucleic acid diagnostics. Expert Rev Med Devic. 2010;7:529–539. doi: 10.1586/erd.10.22. [DOI] [PubMed] [Google Scholar]
- 11.Weiss JB. DNA Probes and Pcr for Diagnosis of Parasitic Infections. Clin Microbiol Rev. 1995;8:113–130. doi: 10.1128/CMR.8.1.113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Srivastava, P., Mehrotra, S., Tiwary, P., Chakravarty, J. & Sundar, S. Diagnosis of Indian Visceral Leishmaniasis by Nucleic Acid Detection Using PCR. PloS one6 (2011). [DOI] [PMC free article] [PubMed]
- 13.Caliendo AM, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis. 2013;57(Suppl 3):S139–170. doi: 10.1093/cid/cit578. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ranjan K, Minakshi P, Prasad G. Application of Molecular and Serological Diagnostics in Veterinary Parasitology. The. Journal of Advances in Parasitology. 2016;2:80–99. doi: 10.14737/journal.jap/2015/2.4.80.99. [DOI] [Google Scholar]
- 15.Di Giusto, D. & King, G. C. Single base extension (SBE) with proofreading polymerases and phosphorothioate primers: improved fidelity in single-substrate assays. Nucleic Acids Res31, (2003). [DOI] [PMC free article] [PubMed]
- 16.Cantacessi C, Dantas-Torres F, Nolan MJ, Otranto D. The past, present, and future of Leishmania genomics and transcriptomics. Trends Parasitol. 2015;31:100–108. doi: 10.1016/j.pt.2014.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Choi S. Powering point-of-care diagnostic devices. Biotechnology advances. 2016;34:321–330. doi: 10.1016/j.biotechadv.2015.11.004. [DOI] [PubMed] [Google Scholar]
- 18.Mahato K, Maurya PK, Chandra P. Fundamentals and commercial aspects of nanobiosensors in point-of-care clinical diagnostics. 3 Biotech. 2018;8:149. doi: 10.1007/s13205-018-1148-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Chandra, P. Nanobiosensors for Personalized and Onsite Biomedical Diagnosis. 640 (2016).
- 20.Kosack CS, Page AL, Klatser PR. A guide to aid the selection of diagnostic tests. Bulletin of the World Health Organization. 2017;95:639–645. doi: 10.2471/BLT.16.187468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Drain PK, et al. Diagnostic point-of-care tests in resource-limited settings. The Lancet. Infectious diseases. 2014;14:239–249. doi: 10.1016/S1473-3099(13)70250-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Sher M, Zhuang R, Demirci U, Asghar W. Paper-based analytical devices for clinical diagnosis: recent advances in the fabrication techniques and sensing mechanisms. Expert Rev Mol Diagn. 2017;17:351–366. doi: 10.1080/14737159.2017.1285228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Rozand C. Paper-based analytical devices for point-of-care infectious disease testing. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2014;33:147–156. doi: 10.1007/s10096-013-1945-2. [DOI] [PubMed] [Google Scholar]
- 24.Gootenberg JS, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356:438–+. doi: 10.1126/science.aam9321. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Gootenberg JS, et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360:439–444. doi: 10.1126/science.aaq0179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Teengam P, et al. Multiplex Paper-Based Colorimetric DNA Sensor Using Pyrrolidinyl Peptide Nucleic Acid-Induced AgNPs Aggregation for Detecting MERS-CoV, MTB, and HPV Oligonucleotides. Analytical chemistry. 2017;89:5428–5435. doi: 10.1021/acs.analchem.7b00255. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Bowler FR, Diaz-Mochon JJ, Swift MD, Bradley M. DNA analysis by dynamic chemistry. Angewandte Chemie. 2010;49:1809–1812. doi: 10.1002/anie.200905699. [DOI] [PubMed] [Google Scholar]
- 28.Bradley, M. & Díaz-Mochón, J. J. Nucleobase characterisation. WO2009037473 A2 (2009).
- 29.Angélica Luque-González M, et al. Identification of Trypanosomatids by detecting Single Nucleotide Fingerprints using DNA analysis by dynamic chemistry with MALDI-ToF. Talanta. 2018;176:299–307. doi: 10.1016/j.talanta.2017.07.059. [DOI] [PubMed] [Google Scholar]
- 30.Li S, et al. A reverse dot blot assay for the screening of twenty mutations in four genes associated with NSHL in a Chinese population. PloS one. 2017;12:e0177196. doi: 10.1371/journal.pone.0177196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Schollen E, Vandenberk P, Cassiman JJ, Matthijs G. Development of reverse dot-blot system for screening of mitochondrial DNA mutations associated with Leber hereditary optic atrophy. Clin Chem. 1997;43:18–23. [PubMed] [Google Scholar]
- 32.Steinlein LM, Crawford JT. Reverse dot blot assay (insertion site typing) for precise detection of sites of IS6110 insertion in the Mycobacterium tuberculosis genome. J Clin Microbiol. 2001;39:871–878. doi: 10.1128/JCM.39.3.871-878.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Stothard DR. Use of a reverse dot blot procedure to identify the presence of multiple serovars in Chlamydia trachomatis urogenital infection. J Clin Microbiol. 2001;39:2655–2659. doi: 10.1128/JCM.39.7.2655-2659.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Sutcharitchan P, et al. Reverse dot-blot detection of the African-American beta-thalassemia mutations. Blood. 1995;86:1580–1585. [PubMed] [Google Scholar]
- 35.Tian G, et al. Quantitative dot blot analysis (QDB), a versatile high throughput immunoblot method. Oncotarget. 2017;8:58553–58562. doi: 10.18632/oncotarget.17236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Diaz-Mochon, J. J., Fara, A. M., Tabraue, M., Pernagallo, S. & Ilyine, H. Improved PNA Probe (2016).
- 37.He G, Rapireddy S, Bahal R, Sahu B, Ly DH. Strand invasion of extended, mixed-sequence B-DNA by gammaPNAs. Journal of the American Chemical Society. 2009;131:12088–12090. doi: 10.1021/ja900228j. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Pham HH, et al. Cooperative hybridization of gamma PNA miniprobes to a repeating sequence motif and application to telomere analysis. Organic & biomolecular chemistry. 2014;12:7345–7354. doi: 10.1039/C4OB00953C. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Sacui J, Hsieh WC, Manna A, Sahu B, Ly DH. Gamma Peptide Nucleic Acids: As Orthogonal Nucleic Acid Recognition Codes for Organizing Molecular Self-Assembly. Journal of the American Chemical Society. 2015;137:8603–8610. doi: 10.1021/jacs.5b04566. [DOI] [PubMed] [Google Scholar]
- 40.De Costa NT, Heemstra JM. Evaluating the effect of ionic strength on duplex stability for PNA having negatively or positively charged side chains. PloS one. 2013;8:e58670. doi: 10.1371/journal.pone.0058670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Rissin DM, et al. Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: Detection of drug-induced liver injury. PloS one. 2017;12:e0179669. doi: 10.1371/journal.pone.0179669. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Venkateswaran S, et al. Novel bead-based platform for direct detection of unlabelled nucleic acids through Single Nucleobase Labelling. Talanta. 2016;161:489–496. doi: 10.1016/j.talanta.2016.08.072. [DOI] [PubMed] [Google Scholar]
- 43.Xue Y, O'Mara ML, Surawski PP, Trau M, Mark AE. Effect of poly(ethylene glycol) (PEG) spacers on the conformational properties of small peptides: a molecular dynamics study. Langmuir: the ACS journal of surfaces and colloids. 2011;27:296–303. doi: 10.1021/la103800h. [DOI] [PubMed] [Google Scholar]
- 44.Verma S, et al. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. PloS one. 2010;5:e10107. doi: 10.1371/journal.pone.0010107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Mulindwa J, et al. Methods to determine the transcriptomes of trypanosomes in mixtures with mammalian cells: the effects of parasite purification and selective cDNA amplification. PLoS Negl Trop Dis. 2014;8:e2806. doi: 10.1371/journal.pntd.0002806. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data and information are available upon request.